120 Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5).
79. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA,
et al. Alzheimer's disease is not “brain aging”:
Neuropathological, genetic, and epidemiological human studies.
Acta Neuropathol 2011;121:571-87.
80. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-
Grau S, Amin N, et al. New insights into the genetic etiology of
Alzheimer’s disease and related dementias. Nat Genet
2022;54:412-36.
81. Loy CT, Schofield PR, Turner AM, Kwok JBJ. Genetics of
dementia. Lancet 2014;383:828-40.
82. Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J,
et al. APOE-related risk of mild cognitive impairment and
dementia for prevention trials: An analysis of four cohorts.
PLoS Med 2017;14(3):e1002254.
83. Spinney L. Alzheimer’s disease: The forgetting gene. Nature
2014;510(7503):26-8.
84. Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN,
et al. Prevalence of apolipoprotein e4 genotype and
homozygotes (APOE e4/4) among patients diagnosed with
Alzheimer’s disease: A systematic review and meta-analysis.
Neuroepidemiology 2012;38:1-17.
85. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD,
et al. Utility of the apolipoprotein E genotype in the diagnosis
of Alzheimer’s disease. N Engl J Med 1998;338:506-11.
86. Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC,
Scherr PA, et al. Incidence of Alzheimer disease in a biracial
urban community: Relation to apolipoprotein E allele status.
Arch Neurol 2003;60(2):185-9.
87. Tang M, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, et al.
The APOE-e4 allele and the risk of Alzheimer disease among
African Americans, whites, and Hispanics. JAMA 1998;279:751-55.
88. Weuve J, Barnes LL, Mendes de Leon CF, Rajan KB, Beck T,
Aggarwal NT, et al. Cognitive aging in black and white
Americans: Cognition, cognitive decline, and incidence of
Alzheimer disease dementia. Epidemiology 2018;29(1):151-9.
89. Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C,
Ogunniyi A, et al. APOE 4 and the risk for Alzheimer disease
and cognitive decline in African Americans and Yoruba. Int
Psychogeriatr 2014;26(6):977-85.
90. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS,
et al. Variants in the ATP-binding cassette transporter (ABCA7),
apolipoprotein E epsilon 4, and the risk of late-onset Alzheimer
disease in African Americans. JAMA 2013;309(14):1483-92.
91. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis
SM, et al. Associations between midlife vascular risk factors and
25-year incident dementia in the Atherosclerosis Risk in
Communities (ARIC) cohort. JAMA Neurol 2017;74(10):1246-54.
92. Bakulski KM, Vadari HS, Faul JD, Heeringa SG, Kardia SLR,
Langa KM, et al. Cumulative genetic risk and APOE «4 are
independently associated with dementia status in a multiethnic,
population-based cohort. Neurol Genet 2021;7:e576.
93. Rajan KB, Barnes LL, Wilson RS, McAninch EA, Weuve J,
Sighoko D, et al. Racial differences in the association between
apolipoprotein E risk alleles and overall and total cardiovascular
mortality over 18 years. JAGS 2017;65:2425-30.
94. Kataoka S, Robbins DC, Cowan LD, Go O, Yeh JL, Devereux RB,
et al. Apolipoprotein E polymorphism in American Indians and
its relation to plasma lipoproteins and diabetes. The Strong
Heart Study. Arterioscler Thromb Vasc Biol 1996;16:918-25.
95. Le Guen Y, Raulin AC, Logue MW, Sherva R, Belloy ME, Eger
SJ, et al. Association of African ancestry-specific APOE
missense variant R145C with risk of Alzheimer disease. JAMA
2023;329(7):551-60.
96. Granot-Hershkovitz E, Tarraf W, Kurniansyah N, Daviglus M,
Isasi CR, Kaplan R, et al. APOE alleles’ association with cognitive
function differs across Hispanic/Latino groups and genetic
ancestry in the study of Latinos-investigation of
neurocognitive aging (HCHS/SOL). Alzheimer’s Dement
2021;17:466-74.
97. Lott IT, Dierssen M. Cognitive deficits and associated
neurological complications in individuals with Down’s
syndrome. Lancet Neurol 2010;9(6):623-33.
98. National Down Syndrome Society. Alzheimer’s Disease and
Down Syndrome. Available at: https://www.ndss.org/resources/
alzheimers/. Accessed December 15, 2023.
99. Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L,
Barroeta I, et al. Clinical and biomarker changes of Alzheimer's
disease in adults with Down syndrome: A cross-sectional study.
Lancet 2020;395(10242):1988-97.
100. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-
Iragui M. Alzheimer's disease associated with Down syndrome:
A genetic form of dementia. Lancet Neurol 2021;20(11):930-42.
101. Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher
EMC, et al. Association of dementia with mortality among
adults with Down syndrome older than 35 years. JAMA Neurol
2019;76(2):152-60.
102. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer
disease. J Geriatr Psychiatry Neurol 2010;23(4):213-27.
103. Goldman JS, Hahn SE, Bird T. Genetic counseling and testing
for Alzheimer disease: Joint practice guidelines of the American
College of Medical Genetics and the National Society of
Genetic Counselors. Genet Med 2011;13:597-605.
104. Lopera F, Marino C, Chandrahas AS, O'Hare M, Villalba-Moreno
ND, Aguillon D, et al. Resilience to autosomal dominant
Alzheimer's disease in a Reelin-COLBOS heterozygous man.
Nat Med 2023 May;29(5):1243-52.
105. Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S,
Marino C, Chmielewska N, et al. Resistance to autosomal
dominant Alzheimer's disease in an APOE3 Christchurch
homozygote: a case report. Nat Med 2019;25(11):1680-83.
106. Wolters FJ, van der Lee SJ, Koudstaal PJ, van Duijn CM,
Hofman A, Ikam MK, et al. Parental family history of dementia
in relation to subclinical brain disease and dementia risk.
Neurology 2017;88:1642-9.
107. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C,
Banerjee S, et al. Dementia prevention, intervention, and care:
2020 report of the Lancet Commission. Lancet 2020; 396
(10248):413-46.
108. Rosenwohl-Mack A, Yaffe K, Carrasco A, Hoffmann CM, Barnes
DE. Risk factors associated with Alzheimer disease and related
dementias by sex and race and ethnicity in the US. JAMA
Neurol 2022;79(6):584-91.
109. World Health Organization. Risk reduction of cognitive decline
and dementia: WHO guidelines. https://www.who.int/
publications/i/item/risk-reduction-of-cognitive-decline-and-
dementia. Accessed December 15, 2023.
110. Institute of Medicine. Cognitive Aging: Progress in
Understanding and Opportunity for Action. Washington, D.C.:
The National Academies Press; 2015.
111. James BD, Bennett DA. Causes and patterns of dementia: An
update in the era of redefining Alzheimer's disease. Ann Rev
Public Health. 2019;40:65-84.
112. Mergenthaler P, Lindauer U, GA Dienel, Meisel A. Sugar for the
brain: The role of glucose in physiological and pathological
brain function. Trends Neurosci 2013;36(10):587-97.
113. Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC,
Llewellyn DJ. Stroke and dementia risk: A systematic review
and meta-analysis. Alzheimers Dement 2018;14(11):1416-26.
114. Samieri C, Perier MC, Gaye B, Proust-Lima C Helmer C,
Dartigues JF, et al. Association of cardiovascular health level in
older age with cognitive decline and incident dementia. JAMA
2018;320(7):657-64.
115. Rönnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular risk
factors and dementia: 40-year follow-up of a population-based
cohort. Dement Geriatr Cogn Disord 2011;31(6):460-6.
116. Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley
M, et al. Association between systolic blood pressure and
dementia in the Whitehall II cohort study: Role of age, duration,
and threshold used to define hypertension. Eur Heart J
2018;39(33):3119-25.
117. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C,
et al. Midlife vascular risk factor exposure accelerates structural
brain aging and cognitive decline. Neurology 2011;77:461-8.